Blog

Neuromics is proud to introduce our newest pioneering research tools - human Cas9 expressing primary cells and GPCR expressing cell lines. With these modifications, the cells are valuable and versatile options for drug discovery, studying disease mechanisms, and countless other applications.

Our Cas9 expressing human primary cells have been genetically modified to express the Cas9 protein in a stable manner. Engineered to continuously produce and maintain the expression of the Cas9 protein, they can be used for precise and consistent CRISPR-based genome editing.

Image: Human retinal microvascular endothelial cells (HRMECs) in culture.

We are starting by offering six types of Cas9 expressing primary cells, including endothelial cells and fibroblasts. However, we will add dozens more in the future. Please contact us if there are any other types you need.

G-Protein Coupled Receptors (GPCRs) are at the forefront of modern drug discovery research, playing a vital role in various signal transduction pathways. We are starting by offering two of the most studied and used cell lines, GPCR expressing HEK293 and CHO-K1 cells.

When discussing our primary antibodies for pain and neuroscience research, we always point to the 20+ years of results. Why wouldn't we? That's quite an accomplishment. Several of these antibodies have been consistently used in published research for over two decades. Over the weekend, two more studies were released using our antibodies in these familiar applications.

Image: Increased expression of mu opioid receptor levels in the ipsilateral lumbar DRGs of CPSS rats.

Researchers from Johns Hopkins University released pain research with the help of our rabbit Mu Opioid Receptor antibody (cat. RA10104). The paper introduced a rat model to study chronic pain after spine surgery (CPSS). By performing surgery on the rats and looking for symptoms of CPSS after the procedure, it provides a model to study the mechanisms of the disorder. You can read the full paper here.

Along with our often-featured human cells, media, and antibodies, Neuromics offers a large selection of recombinant proteins. We'd like to focus on ISOKine recombinant proteins, which use a unique technology for their production. Furthermore, one was used in a newly released study.

Researchers from the Department of Developmental BioEngineering at the University of Twente used our ISOKine Human Fibroblast Growth Factor basic (bFGF) recombinant protein (cat. PR80001) in 3D bioprinting research published earlier this month. The bFGF was used to supplement media for the culture of human mesenchymal stem cells. The scientists introduced a dual cross-linkable hydrogel with the potential to produce engineered tissues, drug discovery models, and lab-grown meat. Read the full study here.

Image: Plant cell system: the barley plant does not contain any pathogens or other components known to be harmful for human or animal stem cells.

ISOKine plant-based proteins are highly purified, endotoxin-free, and produced in an eco-friendly manner. They are all produced in barley grain (Hordeum vulgare), meaning they are free from animal and human components, antibiotics, and contaminants. The proteins are perfect for use in stem cell culture. Read more to explore our options.

Our primary human endothelial cells have a distinguished resume of enabling research across a wide spectrum of applications. Just a few months ago, we highlighted the use of our human brain microvascular endothelial cells (HBMECs) (cat. HEC02) in an aging study that looked at cell senescence. However, if there is one area where our endothelial cells stand out, it's in diabetes research.

These cells have been utilized on several occasions to study and learn about how endothelial cells react to different glucose environments. Our endothelial cells were part of a study that proposed a drug to treat diabetic retinopathy. You can review all the ways our endothelial cells are being used here.

Image: Endothelial cells from different vascular beds display heterogeneous mitochondrial network morphology.

Then, just this past week, researchers at the University of Glasgow published a paper using our HBMECs to study diabetes.

Our reagents have a long history of enabling neurodegenerative disease research. Some of the highlights include our Human 3D Blood-Brain Barrier (BBB) Model (cat. 3D45002) being used in Alzheimer's research and our Rabbit Polyclonal GFAP antibody (cat. RA22101) being utilized in a Parkinson's disease study. Then, we see there is a just-released study that will be immediately added to the highlight reel.

Researchers from the Mayo Clinic used our Premium US Origin Fetal Bovine Serum (FBS) (cat. FBS001) to culture HEK293E cells and primary human dermal fibroblasts in a new publication. The investigators focused their research on PINK1, a protein involved in mitophagy. They set out to build a method to sensitively detect and quantify PINK1 protein expression, which previously did not exist.

The scientists developed a sandwich ELISA to measure PINK1 levels in various cells. The research will have major implications for further understanding the involvement of PINK1 in neurodegenerative diseases, especially Parkinson’s and Alzheimer’s. You can read the full paper here.